Abstract
AbstractThe purpose of this retrospective study was to investigate response of sinonasal mucosal melanoma (SMM) patients to treatment with immune checkpoint inhibitors (ICI), using hybrid PET imaging. Fifteen SMM patients underwent hybrid PET imaging before and three months after initiation of ICI. The disease-specific survival (DSS) was calculated. Quantitative PET parameters of the primary tumor and their association with DSS and therapy response were investigated. Nine of the fifteen (60%) patients responded to ICI therapy. Patients with therapy response depicted on hybrid PET imaging had better DSS than those without (p = 0.0058). Quantitative PET parameters of the initial PET harbored no association with DSS or therapy response. However, these findings lack of sufficient statistical power and must be interpreted with caution. The first restaging PET-imaging after ICI initiation can help stratify patients with regard to DSS.
Funder
GE | GE Healthcare
Alfred and Annemarie von Sick legacy
Clinical Research Priority Program (CRPP) Artificial Intelligence in Oncological Imaging Network
Honoraria and travel support from Pierre Fabre, Merck Sharp & Dohme, Bristol Myers Squibb and Sun Pharma
Employee of Oncobit AG
Publisher
Springer Science and Business Media LLC